NASDAQ:PRFX PainReform (PRFX) Stock Price, News & Analysis $1.46 +0.01 (+0.62%) As of 12:52 PM Eastern This is a fair market value price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesSEC FilingsShort InterestTrendsBuy This Stock About PainReform Stock (NASDAQ:PRFX) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get PainReform alerts:Sign Up Key Stats Today's Range$1.34▼$1.4750-Day Range$1.45▼$2.8852-Week Range$1.28▼$17.95Volume54,274 shsAverage Volume682,154 shsMarket Capitalization$583.60 thousandP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingSell Company Overview PainReform Ltd., a clinical stage specialty pharmaceutical company, focuses on the reformulation of established therapeutics and provides an extended period of post-surgical pain relief in Israel. It develops PRF-110, a viscous clear oil-based solution that is instilled directly into the surgical wound to provide localized and extended post-operative analgesia, as well as in Phase 3 clinical trial for pain treatment of patients undergoing bunionectomy and second trial for pain treatment of hernia repair operations. The company was incorporated in 2007 and is based in Tel Aviv, Israel. Read More PainReform Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks15th Percentile Overall ScorePRFX MarketRank™: PainReform scored higher than 15% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion0.7 / 5Analyst RatingSell Consensus RatingPainReform has received a consensus rating of Sell. The company's average rating score is 1.00, and is based on no strong buy ratings, no buy ratings, no hold ratings, and 1 sell rating.Amount of Analyst CoveragePainReform has only been the subject of 1 research reports in the past 90 days.Read more about PainReform's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of PainReform is 0.00, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of PainReform is 0.00, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioPainReform has a P/B Ratio of 0.06. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Short Interest4.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted27.91% of the float of PainReform has been sold short.Short Interest Ratio / Days to CoverPainReform has a short interest ratio ("days to cover") of 0.65, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in PainReform has recently decreased by 12.90%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldPainReform does not currently pay a dividend.Dividend GrowthPainReform does not have a long track record of dividend growth. News and Social MediaN/ANews SentimentN/A Company Ownership1.2 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, PainReform insiders have not sold or bought any company stock.Percentage Held by Insiders34.40% of the stock of PainReform is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions37.28% of the stock of PainReform is held by institutions.Read more about PainReform's insider trading history. Receive PRFX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for PainReform and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. PRFX Stock News HeadlinesPRF Technologies Announces FDA Clearance of IND Application for OcuRing™-K Phase II Clinical TrialApril 28, 2026 | globenewswire.comPRF Technologies Provides Year-End 2025 Business Update Highlighting Strategic Progress Across Healthcare and AI-Driven Solar PlatformsMarch 27, 2026 | globenewswire.comYour book attachedBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time through a temporary download link. He plans to charge for it soon. Download your copy now and lock it in at no cost, regardless of future pricing.May 22 at 1:00 AM | Profits Run (Ad)PRF Technologies Ltd. Announces Commercial Collaboration Agreement with Blade Ranger to Accelerate Large-Scale DeepSolar Commercial EngagementsMarch 17, 2026 | globenewswire.comPRF Technologies’ DeepSolar Announces its First Commercial Due Diligence Engagement with EDF Power Solutions Israel, a Global Leader in Renewable EnergyFebruary 18, 2026 | markets.businessinsider.comPRF Technologies' DeepSolar Announces its First Commercial Due Diligence Engagement with EDF Power Solutions Israel, a Global Leader in Renewable EnergyFebruary 18, 2026 | globenewswire.comPRF Technologies Wins Another European Utility-Scale Solar Deployment, Expanding DeepSolar's Installed Commercial BaseFebruary 11, 2026 | globenewswire.comPRF Technologies Files Its First Patent Application for Solar Plant Micro-Climate Forecast Modeling Designed to Improve Energy Production Forecast AccuracyJanuary 20, 2026 | globenewswire.comSee More Headlines PRFX Stock Analysis - Frequently Asked Questions How have PRFX shares performed this year? PainReform's stock was trading at $3.2090 at the start of the year. Since then, PRFX shares have decreased by 57.2% and is now trading at $1.3750. How were PainReform's earnings last quarter? PainReform Ltd. (NASDAQ:PRFX) announced its quarterly earnings data on Thursday, March, 26th. The company reported ($1.01) earnings per share for the quarter. When did PainReform's stock split? PainReform's stock reverse split on the morning of Thursday, November 21st 2024.The 1-4 reverse split was announced on Monday, November 18th 2024. The number of shares owned by shareholders was adjusted after the market closes on Wednesday, November 20th 2024. An investor that had 100 shares of stock prior to the reverse split would have 25 shares after the split. When did PainReform IPO? PainReform (PRFX) raised $23 million in an IPO on Tuesday, September 1st 2020. The company issued 2,550,000 shares at a price of $8.00-$10.00 per share. Maxim Group and Joseph Gunnar served as the underwriters for the IPO. How do I buy shares of PainReform? Shares of PRFX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of PainReform own? Based on aggregate information from My MarketBeat watchlists, some other companies that PainReform investors own include Predictive Oncology (POAI), Bank of America (BAC), Ford Motor (F), JPMorgan Chase & Co. (JPM), Wells Fargo & Company (WFC), Abbott Laboratories (ABT) and Zomedica (ZOM). Company Calendar Last Earnings3/26/2026Today5/22/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Red Zone (2m+) 1-Year History May 25 Aug 25 Nov 25 Feb 26 May 26 PRFX's financial health is in the Red zone, according to TradeSmith. PRFX has been in this zone for over 2 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - DRUGS Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:PRFX CIK1801834 Webwww.painreform.com Phone972-3717-7051FaxN/AEmployees4Year FoundedN/AProfitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current Ratio1.78 Quick Ratio1.78 Sales & Book Value Annual Sales$20 thousand Price / Sales29.18 Cash FlowN/A Price / Cash FlowN/A Book Value$23.07 per share Price / Book0.06Miscellaneous Outstanding Shares400,000Free Float264,000Market Cap$583.60 thousand OptionableNot Optionable Beta0.77 5G Stocks: The Path Forward is ProfitableClick the link to see MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free Report This page (NASDAQ:PRFX) was last updated on 5/22/2026 by MarketBeat.com Staff. From Our PartnersHow to Profit from Elon’s AI lab before it goes publicElon Musk's AI lab has partnered with the Department of Defense, Oracle, and Palantir - and he just filed conf...InvestorPlace | SponsoredMaybe the Greatest Strategy of the DecadeNate Bear, Lead Technical Tactician at Monument Traders Alliance, is going public with his highest-conviction ...Monument Traders Alliance | SponsoredA letter from Shannon StansberryPorter Stansberry nearly canceled the entire project. When he first saw the claimed returns - only one down ye...Porter & Company | SponsoredThe SpaceX supplier that shipped 5 billion chips to StarlinkWhen Nvidia surged 770%, its data center cooling supplier Vertiv climbed 1,700%. When Apple ran 2,000%, suppli...Weiss Ratings | SponsoredYour $29.97 book is free todayWhy Some Traders Skip Stocks Entirely You don't need a big account to trade options. In fact, options ca...Profits Run | SponsoredOne filing just changed the SpaceX IPO foreverSpaceX just filed its S-1. The IPO is confirmed for June 12 - $75 billion, ticker SPCX, potentially the larges...Behind the Markets | SponsoredSpaceX controls two-thirds of all satellites - and it is about to go publicSpaceX is targeting an IPO on June 11th, with trading set to begin June 12th and the roadshow kicking off June...NXT Wave Research | SponsoredTo Avoid 67 Million Blackouts, Trump Signs Emergency Backing of New Energy TechPresident Trump has used emergency executive powers to back a new energy technology described as 326 times mor...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding PainReform Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share PainReform With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
